Eton Pharmaceuticals (ETON) grants 10,000 performance RSUs to director
Rhea-AI Filing Summary
RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Norbert G. Riedel received a grant of 10,000 performance-vested restricted stock units (RSUs) on July 31, 2026 under the 2018 equity incentive plan. Each RSU represents one common share and vests in full if the stock’s closing price reaches $72.36 or higher for one trading day before July 31, 2029; otherwise the entire award is forfeited. Following this grant, Riedel holds 10,000 such units.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
RIEDEL NORBERT G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 10,000 shares (Direct)
Footnotes (1)
- F1. On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
Key Figures
RSUs granted: 10,000 shares
Transaction price: $0.0000 per share
Vesting price hurdle: $72.36 per share
3 metrics
RSUs granted
10,000 shares
Performance-vested restricted stock units granted to director on July 31, 2026
Transaction price
$0.0000 per share
RSU grant made at no cash cost to the director
Vesting price hurdle
$72.36 per share
Closing price required on one trading day before July 31, 2029 for RSUs to vest
Key Terms
performance-vested restricted stock units, equity incentive plan, market condition, forfeited
4 terms
performance-vested restricted stock units financial
"granted 10,000 performance-vested restricted stock units under the Issuer's 2018 equity incentive plan"
equity incentive plan financial
"granted under the Issuer's 2018 equity incentive plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
market condition financial
"If this market condition is not satisfied prior to such date"
forfeited financial
"the award will be forfeited in its entirety without consideration"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider equity award did ETON grant to Norbert G. Riedel?
Eton Pharmaceuticals granted director Norbert G. Riedel 10,000 performance-vested restricted stock units (RSUs) on July 31, 2026. Each RSU equals one common share and depends entirely on achieving a specific stock-price condition before July 31, 2029.
What is the vesting condition for Norbert G. Riedel’s ETON RSUs?
The RSUs vest only if Eton Pharmaceuticals’ stock closes at or above $72.36 per share for one trading day before July 31, 2029. If this market condition is not satisfied in time, none of the 10,000 RSUs will vest.
What happens to ETON’s 10,000 RSUs if the price hurdle is not met?
If the $72.36 stock-price condition is not reached for one trading day by July 31, 2029, the entire 10,000-unit RSU award is forfeited without consideration. Riedel would then receive no shares from this grant.
How many ETON units does Norbert G. Riedel hold after this transaction?
Following the grant, Norbert G. Riedel is reported as holding 10,000 performance-vested RSUs linked to Eton Pharmaceuticals common stock. These units may convert into 10,000 shares only if the specified $72.36 stock-price condition is achieved in time.
Under which plan were Norbert G. Riedel’s ETON RSUs granted?
The 10,000 performance-vested RSUs for Norbert G. Riedel were granted under Eton Pharmaceuticals’ 2018 equity incentive plan. This plan provides stock-based awards, such as RSUs, that align director and executive compensation with the company’s share-price performance.